Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 13Multiple Myeloma 3Carcinoma, Renal Cell 3Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1Hematologic Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 34fludarabine 25fludarabine phosphate 24Tacrolimus 24Mycophenolic Acid 23Whole-Body Irradiation 22Busulfan 15Methotrexate 12Melphalan 12Granulocyte Colony-Stimulating Factor 12Antilymphocyte Serum 12thymoglobulin 11Cyclosporine 11Stem Cell Transplantation 10Filgrastim 10Rituximab 9Thiotepa 7Peripheral Blood Stem Cell Transplantation 7Nivolumab 7Dexamethasone 7trametinib 6Radiotherapy 6Mesna 6Cytarabine 6Prednisone 5Calcium Dobesilate 5Bortezomib 5Azacitidine 5Alemtuzumab 5Voriconazole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hematologic Neoplasms × Introns × Clear all
NCT04379518 2026-01-13

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Roswell Park Cancer Institute

Phase 1/2 Terminated
4 enrolled 30 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡